AbbVie, Neurocrine report a PhIII win for blockbuster contender elagolix

John Carroll

investigators delivered a fresh set up promising results for a key late-stage drug in the pipeline. In the first of two Phase III studies, the company reports that both doses of scored statistically significant results for chronic and painful cases of endometriosis among pre-menopausal women.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS